Trials / Unknown
UnknownNCT02886559
Chidamide Plus DCAG for Relapsed/Refractory AML
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 59 Years
- Healthy volunteers
- Not accepted
Summary
Despite advances in understanding the complexities of acute myeloid leukaemia (AML), the treatment of refractory or relapsed AML (rrAML) remains a daunting clinical challenge.The investigators designed a new regimen, including chidamide, decitabine, aclarubincin, cytarabine and G-CSF, to treat rrAML.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chidamide plus DCAG regimen | chidamide, decitabine, aclarubicin, cytarabine and G-CSF |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2018-06-01
- Completion
- 2019-06-01
- First posted
- 2016-09-01
- Last updated
- 2018-02-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02886559. Inclusion in this directory is not an endorsement.